<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03542357</url>
  </required_header>
  <id_info>
    <org_study_id>H-16000065</org_study_id>
    <nct_id>NCT03542357</nct_id>
  </id_info>
  <brief_title>The Effect of Sumatriptan and Placebo on CGRP Induced Headache</brief_title>
  <official_title>The Effect of Sumatriptan and Placebo on CGRP Induced Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To develop a pragmatic migraine model the investigators will induce headache in healthy
      volunteers and in patients with migraine without aura with aCalcitonine Gene Related Peptide
      (CGRP). If the headache responds to sumatriptan, the model can be used to test new drug
      candidates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There remains a great need for more effective anti-migraine drugs with fewer side effects.
      Human experimental models are valuable in early phase development of new anti-migraine drugs
      but useful models have not yet been developed. The investigators' group has shown that
      Calcitonine Gene Related Peptide (CGRP) induce headache/migraine in both healthy volunteers
      and in patients with migraine without aura (MO). To validate this model, the headache must
      respond to specific migraine treatment with sumatriptan.

      Hypothesis: CGRP induces a migraine-like headache in both healthy subjects and in MO-patients
      and induced headache responds to a specific anti migraine drug; sumatriptan.

      Aim: Developing a pragmatic and valid model for the testing of new anti-migraine drugs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2018</start_date>
  <completion_date type="Actual">September 1, 2018</completion_date>
  <primary_completion_date type="Actual">September 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC after infusion</measure>
    <time_frame>1 year</time_frame>
    <description>The investigators will assess the outcome measures 1 year after the beginning of the study</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Sumatriptan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>headache is induced with CGRP. This headache is treated double-blinded with 1 tablet of sumatriptan 50 mg as a pre-treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>headache is induced with CGRP. This headache is treated double-blinded with 1 tablet of placebo as a pre-treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitonin Gene Related Peptide</intervention_name>
    <description>CGRP is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sumatriptan</arm_group_label>
    <other_name>CGRP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sumatriptan 50 mg</intervention_name>
    <description>CGRP is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan</description>
    <arm_group_label>Sumatriptan</arm_group_label>
    <other_name>Imigran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>CGRPis given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Healthy:

        Healthy subjects of both sexes Age 18-60 years Weight 45-95 kg. Females were requested to
        use effective contraception.

        Migraine patients:

        Migraine patients who meet IHS criteria for migraine with or without aura of both sexes
        18-60 years 45-95 kg.

        Exclusion Criteria:

        Healthy:

        Any type of headache (except episodic tension-type headache &lt; 1 day per week) Serious
        somatic or psychiatric disease Pregnancy Intake of daily medication (except oral
        contraceptives).

        Migraine patients:

        Any other type of headache then migraine without aura (except episodic tension-type
        headache &lt; 1 day per week) Serious somatic or psychiatric disease Pregnancy Intake of daily
        medication (except oral contraceptives) Triptan non-responders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rigshospitalet Glostrup</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 20, 2017</study_first_submitted>
  <study_first_submitted_qc>May 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2018</study_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Katrine Falkenberg</investigator_full_name>
    <investigator_title>Medical doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitonin</mesh_term>
    <mesh_term>Salmon calcitonin</mesh_term>
    <mesh_term>Sumatriptan</mesh_term>
    <mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
    <mesh_term>Katacalcin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

